190 related articles for article (PubMed ID: 26474873)
1. Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Cui F; Wang W; Wu D; He X; Wu J; Wang M
Clin Transl Oncol; 2016 Jul; 18(7):722-7. PubMed ID: 26474873
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Gremlin promotes non-small cell lung cancer progression.
Yin Y; Yang Y; Yang L; Yang Y; Li C; Liu X; Qu Y
Tumour Biol; 2016 Feb; 37(2):2597-602. PubMed ID: 26392110
[TBL] [Abstract][Full Text] [Related]
3. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.
Sui H; Shi C; Yan Z; Wu M
Oncotarget; 2016 Jul; 7(29):45995-46001. PubMed ID: 27351223
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
6. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
7. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
8. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
9. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
10. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Zhu X; Jiang H; Li J; Xu J; Fei Z
Med Sci Monit; 2016 Apr; 22():1435-41. PubMed ID: 27125283
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
Liu W; Ning J; Li C; Hu J; Meng Q; Lu H; Cai L
Tumour Biol; 2016 May; 37(5):6331-6. PubMed ID: 26628299
[TBL] [Abstract][Full Text] [Related]
13. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
14. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
16. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
20. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
